Medizone International introduces Arkady Mandel MD, PhD, D.Sc as a new member to our team of esteemed consultants.

Dr Mandel graduated from the Russian State Medical University, Moscow, in 1987, and was awarded PhD (1982) and D.Sc (1989) by the Supreme Certification Commission of the U.S.S.R. Ministry of Education and Science. In the U.S.S.R, he was Head of the Department of Advanced Biotherapy in the Central Science Research Institute of Dermatology and Sexually Transmitted Diseases that he founded in 1986, and Research Director of the Science and Research Center for Studying Psoriasis that he co-founded in Moscow in 1989. In 1987, he was awarded the State Medal as an outstanding public health worker of the U.S.S.R for his leadership and contributions to the development of new effective therapeutic techniques and innovative biomedical research. In Canada, from 1990-1997, he has conducted various research projects pertaining to molecular biology, immunology and clinical medicine at University of Toronto and several leading teaching hospitals in Toronto, including Sunnybrook Health Sciences Centre and Toronto Western Hospital.

For the last 25 years, he has conducted studies on the biological effects of oxidative stressors and ozone. He has shown that ozone therapy is particularly useful in cardiovascular disorders, tissue ischemia and chronic inflammation.

In 1997, Dr. Mandel joined Vasogen Inc. as a Senior Research Scientist and was appointed Director of Fundamental and Medical Research in 2000. Dr. Mandel is a member of the Science Advisory Committee of The Global Partnership Program (IGX), an initiative of the G8, the Natural Sciences and Engineering Research Council (NSERC) and the Department of Foreign Affairs and International Trade (DFAIT) Canada. Dr. Mandel is engaged in several scientific advisory groups of the International Science and Technology Center (ISTC) Moscow, Russian Federation, and STCU – the Ukrainian International Science and Technology Center.

Dr. Mandel was elected in 2009 to the Board of Directors of the Canadian Foundation for Global Health (CFGH). Dr. Mandel is one of the coordinators of the Drug Design and Development Targeted Initiative (3D-TI), an initiative of the G8 and International Science and Technology Center (ISTC Moscow, Russian Federation). The 3D-TI is the new effort to promote the sustainability of ISTC beneficiaries in biotechnology, medical engineering and chemistry through the development of novel diagnostics and therapeutics to combat global diseases. The Drug Design and Development Targeted Initiative is available for funding by interested parties/partners, and is in part leveraged by the large-scale support that the Russian and G7 Governments, as well as their partners, are providing to the ISTC beneficiaries.

In addition, the Drug Design and Development Targeted Initiative has been developed in close cooperation with relevant Russian Government industrial and scientific agencies, such as: "Rosprom," "Roszdravnadzor," "Rosnauka," Russian Academy of Science, Russian Academy of Medical Science and the Commonwealth of Independent States governments, industrial and research organizations and is viewed as a promising avenue for the search for and identification of the most promising biomedical innovation and new medical products on Russian and CIS's territory, and for secure opportunities to promote their further business development with possible co-funding by G8 governments. In 2007, Dr. Mandel was elected to represent Canada on the 3D-TI Steering Committee.

Dr. Mandel is a consultant for the DFAIT/STCU Sustainability Plan Program. This program arises from the 2007 U.S. Party request to assist the U.S. State Department’s Science Centers Program in directing its program funds toward specially designed, targeted actions on selected institutes of interest to the U.S. ex-Soviet WMD scientist redirection strategy.

He is the author of over 100 scientific publications, including monographs, book chapters and peer reviewed papers, in many areas including clinical medicine, advanced diagnostics and biotherapy, drug design and development, biochemistry, molecular biology, photobiology, immunology, mechanisms of inhibition of inflammation and apoptotic cells function, and is named inventor on more than 50 international patents.

“In joining our research and development team Dr Mandel will contribute immensely to our understanding of the complex chemistry behind the broad and potent bactericidal interaction of  AsepticSure™” commented Dr Michael Shannon, Medizone’s Director of Medical Affairs, who continued, "Dr Mandel brings to Medizone almost 25 years of experience with ozone and holds over 30 international patents pertaining to ozone related medical applications. His enormous depth of knowledge and expertise in the biochemistry, physiology and immunology associated with ozone medicine will prove invaluable to our Company particularly as we attempt to both expand and fortify our Intellectual Property position internationally".